Who is sponsoring NCT03288025?

NCT03288025 is sponsored by The Cleveland Clinic.

What drugs are being tested in NCT03288025?

Interventions in NCT03288025: Nutrition and Exercise.

What condition does NCT03288025 study?

NCT03288025 studies Pulmonary Arterial Hypertension, Insulin Resistance.

Is NCT03288025 still recruiting?

NCT03288025 is currently active, enrolled. Last updated 24 September 2025.

Last reviewed 2025-09-24 · How we verify

NCT03288025

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)

Active, enrolled NA Last updated 24 September 2025

What this trial tests

NA trial testing Nutrition and Exercise in Pulmonary Arterial Hypertension in 34 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

27 September 2017

Primary endpoint
18 February 2022

30 June 2026

Quick facts

Lead sponsor	The Cleveland Clinic
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	34
Start date	27 September 2017
Primary completion	18 February 2022
Estimated completion	30 June 2026
Sites	1 location across United States

Drugs / interventions tested

Nutrition and Exercise

Conditions studied

Pulmonary Arterial Hypertension — all drugs for Pulmonary Arterial Hypertension →
Insulin Resistance — all drugs for Insulin Resistance →

Sponsor

The Cleveland Clinic

Who can join

Adults 18 to 75, any sex, with Pulmonary Arterial Hypertension or Insulin Resistance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the extent to which diet and exercise may improve PAH through the modulation of insulin sensitivity. The central hypothesis is that dysregulated glucose metabolism elicits a response in PAH patients that can be modified by exercise and diet, thereby leading to improvements in pulmonary vascular disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Exercise-based rehabilitation programmes for pulmonary hypertension.
Morris NR, Kermeen FD, Jones AW, Lee JY, et al · · 2023 · cited 29× · PMID 36947725 · DOI 10.1002/14651858.cd011285.pub3

Verify or expand the search:

Other recruiting trials for Pulmonary Arterial Hypertension

Currently open trials in the same condition.

NCT07391228 — Cognitive Alterations in Pulmonary Arterial Hypertension (PAH) · active not recruiting
NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept · Phase 2 · recruiting
NCT07217522 — Rutgers University Study of the Genetics of Pulmonary Hypertension · recruiting
NCT07013149 — The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension · recruiting
NCT06658522 — Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effec · Phase 4 · recruiting

Other The Cleveland Clinic trials

Trials by the same sponsor.

NCT07218198 — Clinical Decision Support Tool for the Treatment of Uncontrolled Hypertension · NA · not yet recruiting
NCT07442747 — Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS · NA · not yet recruiting
NCT07471464 — Centered Surgery - Preoperative Counseling and Patient Satisfaction · recruiting
NCT07073963 — Virtual Patient Groups for Sarcoidosis Associated Fatigue · NA · recruiting
NCT07363343 — Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03288025 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Cleveland Clinic
Last refreshed: 24 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03288025.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing